Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection
Marcelo Kugelmas, Michael J. Osgood, James F. Trotter, Thomas Bak, Michael Wachs, Lisa Forman, Igal Kam, Gregory T. Everson – 30 December 2003 – We recently reported on a series of patients who experienced acute cellular rejection (ACR) during the treatment of hepatitis C virus (HCV) infection in our posttransplantation cohort. Our hypothesis is that HCV clearance improves hepatic microsomal function, which in turn results in lower trough cyclosporine (CyA) and tacrolimus (TAC) levels, predisposing the patient to ACR.